Table 4.
Therapeutic agents that inhibit inflammasome components and their targeted diseases
| Therapeutic agent | Target | Disease |
|---|---|---|
| Anakinra | IL-1 receptor | RA |
| Rilonacept | IL-1β, IL-1β | CAPS, diabetes, gout |
| Canakinumab | IL-1β | MWS, FCAS |
| GSK1070806 | IL-18 | B-cell non-Hodgkin’s lymphoma, IBD |
| Glyburide | NLRP3 (indirectly) | Type 2 diabetes |
| 16673-34-0 | NLRP3 (indirectly) | Acute myocardial infarction |
| Pralnacasan (VX-740) | Caspase-1 | RA |
| VX-765 | MWS | |
| Parthenolide | Caspase-1/NF-κB (IKKβ kinase activity)/NLRP3 ATPase | Cancer |
| Bay 11-7082 | NFκB (IKKβ kinase activity)/NLRP3 ATPase | Systemic lupus erythematosus |
| Cys-LT receptor antagonist | ASC oligomerization | Allergic rhinitis, asthma, nasal polyposis |
| AZD9056 | P2X7 | RA |
| CE-224535 | P2X7 | RA |
| GSK1482169 | P2X7 | RA |
Abbreviations: ASC, apoptosis-related speck-like protein containing a caspase recruitment domain; ATPase, adenosine triphosphatase; CAPS, cryopyrin-associated periodic syndromes; Cys-LT, cysteinyl leukotriene; FCAS, familial cold autoinflammatory syndrome; IBD, inflammatory bowel disease; IKKβ, inhibitor of κB kinase β; IL, interleukin; MWS, Muckle-wells syndrome; NF-κB, nuclear factor kappa B; P2X7, P2X purinergic receptor 7; RA, rheumatoid arthritis.